Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.

Abstract

Thymosin alpha1 (Ta1) is widely used to treat patients with coronavirus disease 2019 (COVID-19), however, its effect remains unclear. This systematic review and meta-analysis aimed to evaluate the effect of Ta1 as a COVID-19 therapy. PubMed, EMBASE, the Cochrane library, Web of Science, and the reference lists of relevant articles were searched to identify eligible studies. Assessment of heterogeneity was done using the I-squared (I2) test and random/fixed effect analysis was done to determine the risk ratio (RR). We polled the data related to mortality mainly by using Review Manager 5.4. Predefined subgroup analyses and sensitivity analyses were also performed. A total of 9 studies were included, on a total of 5352 (Ta1=1152, control=4200) patient outcomes. Meta-analysis results indicated that Ta1 therapy had no statistically significant effect on mortality [RR 1.03 (0.60, 1.75), p=0.92, I2=90%]. Subgroup analyses demonstrated that the beneficial effect in mortality was associated with mean age＞60years in the Tα1 group [RR 0.68 (0.58, 0.78), p<0.0000.1, I2=0%], the proportion of female≤40% in the Tα1 group [RR 0.67 (0.58, 0.77), p<0.0000.1, I2=0%], and severe/critical COVID-19 patients [RR 0.66 (0.57, 0.76), p<0.0000.1, I2=0%]. Sensitivity analysis further demonstrated the results to be robust. The results of this meta-analysis do not support the use of Ta1 in hospitalized adult COVID-19 patients.